Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Post by Gbathaton Mar 24, 2021 6:41pm
172 Views
Post# 32872120

Mike Gordon is one of the new ProMIS Investors

Mike Gordon is one of the new ProMIS Investors

https://fenwaysportsgroup.com/leadership/

Mike Gordon
 is the President of Fenway Sports Group and has been a partner since 2001. In his role with Fenway Sports Group, Mr. Gordon has been primarily responsible for managing the operations of Liverpool F.C.

Mr. Gordon is a seasoned investor with over 30 years of experience. He formerly served as a Managing Partner of Vinik Asset Management LLC, a Boston-based investment firm that he co-founded in 1996. Prior to that, Mr. Gordon spent nine years at Fidelity Investments as a research analyst and portfolio manager of the Blue Chip Growth Fund.

Mr. Gordon is a trustee in a number of non-profit institutions including the Dana Farber Cancer Institute, The Jimmy Fund, the Liverpool FC Foundation, the Red Sox Foundation, Belmont Hill School, the Boys and Girls Club of Boston and is a member of the Stem Cell Task Force at Boston Children’s Hospital. Mr. Gordon has also served on the Board of Trustees for Tufts University since 2012. Mr. Gordon graduated Phi Beta Kappa with a B.A. degree from Tufts University with highest honors.

<< Previous
Bullboard Posts
Next >>